Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Zhou L, Yu Q, Wei G, Wang L, Huang Y, Hu K, et al. Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019. BMC Cancer. 2021;21(1):606.

Article  PubMed  PubMed Central  Google Scholar 

van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397(10272):410–27.

Article  PubMed  Google Scholar 

Kaur J, Valisekka SS, Hameed M, Bandi PS, Varma S, Onwughalu CJ, et al. Monoclonal gammopathy of undetermined significance: a comprehensive review. Clin Lymphoma Myeloma Leuk. 2023;23(5):e195–212.

Article  CAS  PubMed  Google Scholar 

Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018;378(3):241–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dhodapkar MV, Sexton R, Waheed S, Usmani S, Papanikolaou X, Nair B, et al. Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood. 2014;123(1):78–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Visram A, Soof C, Rajkumar SV, Kumar SK, Bujarski S, Spektor TM, et al. Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients. Blood Cancer J. 2021;11(6):120.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pérez-Persona E, Vidriales M-B, Mateo G, García-Sanz R, Mateos M-V, de Coca AG, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007;110(7):2586–92.

Article  PubMed  Google Scholar 

Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K, et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood. 2007;109(4):1692–700.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002;99(5):1745–57.

Article  CAS  PubMed  Google Scholar 

Anguiano A, Tuchman SA, Acharya C, Salter K, Gasparetto C, Zhan F, et al. Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma. J Clin Oncol. 2009;27(25):4197–203.

Article  CAS  PubMed  PubMed Central  Google Scholar 

López-Corral L, Corchete LA, Sarasquete ME, Mateos MV, García-Sanz R, Fermiñán E, et al. Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies. Haematologica. 2014;99(8):1365–72.

Article  PubMed  PubMed Central  Google Scholar 

Vogel C, Marcotte EM. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet. 2012;13(4):227–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chanukuppa V, Paul D, Taunk K, Chatterjee T, Sharma S, Shirolkar A, et al. Proteomics and functional study reveal marginal zone B and B1 cell specific protein as a candidate marker of multiple myeloma. Int J Oncol. 2020;57(1):325–37.

Article  CAS  PubMed  Google Scholar 

Wu X, Guo J, Chen Y, Liu X, Yang G, Wu Y, et al. The 60-kDa heat shock protein regulates energy rearrangement and protein synthesis to promote proliferation of multiple myeloma cells. Br J Haematol. 2020;190(5):741–52.

Article  CAS  PubMed  Google Scholar 

Ferguson ID, Patino-Escobar B, Tuomivaara ST, Lin YT, Nix MA, Leung KK, et al. The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance. Nat Commun. 2022;13(1):4121.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Giliberto M, Santana LM, Holien T, Misund K, Nakken S, Vodak D, et al. Mutational analysis and protein profiling predict drug sensitivity in multiple myeloma cell lines. Front Oncol. 2022;12:1040730.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yao L, Wang JT, Jayasinghe RG, O’Neal J, Tsai CF, Rettig MP, et al. Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma. Cancer Res. 2023. https://doi.org/10.1158/0008-5472.CAN-22-1769.

Article  PubMed  PubMed Central  Google Scholar 

Ong S-E, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A, et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics. 2002;1(5):376–86.

Article  CAS  PubMed  Google Scholar 

Geiger T, Cox J, Ostasiewicz P, Wisniewski JR, Mann M. Super-SILAC mix for quantitative proteomics of human tumor tissue. Nat Methods. 2010;7:383–5.

Article  CAS  PubMed  Google Scholar 

Zatula A, Dikic A, Mulder C, Sharma A, Vågbø CB, Sousa MML, et al. Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia. Oncotarget. 2017;8(12):19427–42.

Article  PubMed  Google Scholar 

International Myeloma Working G. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the international myeloma working group. Br J Haematol. 2003;121(5):749–57.

Article  Google Scholar 

Roseth Aass K, Nedal TMV, Anshushaug Bouma S, Tryggestad SS, Haukas E, Slordahl TS, et al. Comprehensive small RNA-sequencing of primary myeloma cells identifies miR-105-5p as a predictor of patient survival. Br J Cancer. 2023;128(4):656–64.

Article  CAS  PubMed  Google Scholar 

Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol. 2008;26(12):1367–72.

Article  CAS  PubMed  Google Scholar 

Tyanova S, Albrechtsen R, Kronqvist P, Cox J, Mann M, Geiger T. Proteomic maps of breast cancer subtypes. Nat Commun. 2016;7:10259.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Deeb SJ, D’Souza RC, Cox J, Schmidt-Supprian M, Mann M. Super-SILAC allows classification of diffuse large B-cell lymphoma subtypes by their protein expression profiles. Mol Cell Proteomics. 2012;11(5):77–89.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tyanova S, Temu T, Cox J. The MaxQuant computational platform for mass spectrometry-based shotgun proteomics. Nat Protoc. 2016;11(12):2301–19.

Article  CAS  PubMed  Google Scholar 

Geiszler DJ, Kong AT, Avtonomov DM, Yu F, Leprevost FDV, Nesvizhskii AI. PTM-shepherd: analysis and summarization of post-translational and chemical modifications from open search results. Mol Cell Proteomics. 2021;20:100018.

Article  CAS  PubMed  Google Scholar 

Cox J, Hein MY, Luber CA, Paron I, Nagaraj N, Mann M. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol Cell Proteomics. 2014;13(9):2513–26.

Article